Tracy T Batchelor

List of Publications by Year
in descending order

206	13,814	34105 52	23533 111
papers	citations	h-index	g-index

213	213	213	16747
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 2019, 178, 835-849.e21.	28.9	1,408
2	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	9.4	821
3	Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. Journal of Clinical Oncology, 2005, 23, 5034-5043.	1.6	729
4	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
5	Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96â€“07. Journal of Clinical Oncology, 2003, 21, 1044-1049.	1.6	499
6	Phase II Study of Cediranib, an Oral Panâ€“Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2010, 28, 2817-2823.	1.6	489
7	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2013, 31, 3212-3218.	1.6	489
8	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	12.6	461
9	Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium. Oncologist, 2011, 16, 1589-1599.	3.7	386
10	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	27.8	374
11	Detection of 2-Hydroxyglutarate in IDH -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy. Science Translational Medicine, 2012, 4, 116ra4.	12.4	367
12	Primary CNS Lymphoma. Journal of Clinical Oncology, 2006, 24, 1281-1288.	1.6	329
13	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell, 2015, 28, 773-784.	16.8	327
14	Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS Lymphoma. Journal of Clinical Oncology, 2005, 23, 1507-1513.	1.6	220
15	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. Cancer Discovery, 2014, 4, 1299-1309.	9.4	207
16	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology, 2015, 17, 116-121.	1.2	207
17	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood, 2019, 133, 2212-2221.	1.4	207
18	Treatment of Relapsed Central Nervous System Lymphoma with High-Dose Methotrexate. Clinical Cancer Research, 2004, 10, 5643-5646.	7.0	196

#	Article	IF	Citations
19	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nature Genetics, 2020, 52, 371-377.	21.4	177
20	New Treatment Strategies for Malignant Gliomas. Oncologist, 1999, 4, 209-224.	3.7	147
21	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. Clinical Cancer Research, 2014, 20, 2898-2909.	7.0	146
22	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer, 2022, 128, 47-58.	4.1	132
23	Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement. Neuro-Oncology, 2019, 21, 1412-1422.	1.2	128
24	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clinical Cancer Research, 2016, 22, 1632-1641.	7.0	127
25	Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nature Biomedical Engineering, 2019, 3, 230-245.	22.5	127
26	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. Journal of Neuro-Oncology, 2019, 145, 97-105.	2.9	125
27	High-dose methotrexate for intraocular lymphoma. Clinical Cancer Research, 2003, 9, 711-5.	7.0	121
28	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	7.7	120
29	A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget, 2017, 8, 79298-79304.	1.8	119
30	High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-Oncology, 2009, 11, 211-215.	1.2	115
31	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clinical Cancer Research, 2016, 22, 4452-4465.	7.0	112
32	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro-Oncology, 2015, 17, 862-867.	1.2	111
33	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology, 2017, 35, 361-369.	1.6	109
34	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nature Communications, 2018, 9, 1474.	12.8	106
35	Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood, 2013, 121, 745-751.	1.4	105
36	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology, 2019, 37, 741-750.	1.6	103

#	Article	IF	Citations
37	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	1.2	99
38	Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neuro-Oncology, 2004, 6, 21-27.	1.2	98
39	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology, 2015, 84, 280-286.	1.1	92
40	New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics, 2017, 14, 321-332.	4.4	91
41	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nature Medicine, 2020, 26, 1280-1284.	30.7	83
42	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clinical Cancer Research, 2015, 21, 3610-3618.	7.0	79
43	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Advances, 2019, 3, 375-383.	5.2	77
44	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletionâ€“Mediated Cytotoxicity. Cancer Research, 2017, 77, 4102-4115.	0.9	74
45	Standard chemoradiation for glioblastoma results in progressive brain volume loss. Neurology, 2015, 85, 683-691.	1.1	70
46	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 603-610.	2.9	69
47	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology, 2021, 23, 1056-1071.	1.2	68
48	Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. Journal of Neuro-Oncology, 2016, 126, 157-164.	2.9	64
49	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 1240-1250.	1.2	64
50	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22 27, 851-852.	4.1	63
51	Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro-Oncology, 2019, 21, 306-313.	1.2	63
52	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	1.4	62
53	Supportive Care of Brain Tumor Patients. Hematology/Oncology Clinics of North America, 2006, 20, 1337-1361.	2.2	55
54	Glioblastoma care in the elderly. Cancer, 2016, 122, 189-197.	4.1	53

#	Article	IF	Citations
55	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clinical Cancer Research, 2017, 23, 5745-5756.	7.0	53
56	Primary central nervous system lymphoma: A curable disease. Hematological Oncology, 2019, 37, 15-18.	1.7	53
57	Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro-Oncology, 2020, 22, 94-102.	1.2	53
58	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1386-1392.	1.2	50
59	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. Npj Precision Oncology, 2017, 1, 5.	5.4	49
60	Primary central nervous system lymphoma. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879356.	3.5	48
61	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2020, 26, 206-212.	7.0	48
62	Prospective, high-throughput molecular profiling of human gliomas. Journal of Neuro-Oncology, 2012, 110, 89-98.	2.9	47
63	Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiotherapy and Oncology, 2019, 137, 95-101.	0.6	46
64	Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clinical Cancer Research, 2016, 22, 2885-2896.	7.0	45
65	Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clinical Cancer Research, 2019, 25, 2305-2313.	7.0	43
66	Highâ€dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer, 2017, 123, 3073-3079.	4.1	41
67	Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma. Ocular Immunology and Inflammation, 2021, 29, 507-520.	1.8	41
68	Genotype-targeted local therapy of glioma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8388-E8394.	7.1	40
69	Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro-Oncology, 2018, 20, 642-654.	1.2	39
70	Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. Journal of Neuro-Oncology, 2019, 142, 69-77.	2.9	39
71	Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Translational Oncology, 2015, 8, 137-146.	3.7	38
72	Accelerated progression of IDH mutant glioma after first recurrence. Neuro-Oncology, 2019, 21, 669-677.	1.2	38

#	Article	IF	Citations
73	Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clinical Cancer Research, 2018, 24, 4643-4649.	7.0	37
74	Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. Neuro-Oncology, 2019, 21, 1118-1130.	1.2	37
75	Intraocular Methotrexate Level After High-Dose Intravenous Infusion. Journal of Clinical Oncology, 1999, 17, 1326c-1326c.	1.6	36
76	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. Oncologist, 2019, 24, 671-679.	3.7	36
77	The role of whole brain radiation in primary CNS lymphoma. Blood, 2016, 128, 32-36.	1.4	35
78	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro-Oncology, 2017, 19, now253.	1.2	35
79	Multimodality imaging and mathematical modelling of drug delivery to glioblastomas. Interface Focus, 2016, 6, 20160039.	3.0	34
80	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. Neuro-Oncology, 2018, 20, 174-183.	1.2	33
81	Radiomics Repeatability Pitfalls in a Scan-Rescan MRI Study of Glioblastoma. Radiology: Artificial Intelligence, 2021, 3, e190199.	5.8	32
82	Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutantIDHglioma patients. Neuro-Oncology, 2016, 18, now100.	1.2	30
83	Isocitrate dehydrogenase mutation as a therapeutic target in gliomas. Chinese Clinical Oncology, 2017, 6, 33-33.	1.2	30
84	Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-Î² tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro-Oncology, 2017, 19, now185.	1.2	28
85	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS ONE, 2017, 12, e0180541.	2.5	28
86	Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. Npj Precision Oncology, 2017, 1, 33.	5.4	27
87	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clinical Cancer Research, 2019, 25, 4375-4387.	7.0	26
88	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nature Cancer, 2021, 2, 498-502.	13.2	26
89	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro-Oncology, 2019, 21, 596-605.	1.2	25
90	Primary dural lymphomas: Clinical presentation, management, and outcome. Cancer, 2020, 126, 2811-2820.	4.1	24

#	Article	IF	Citations
91	Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 160-71.	1.0	23
92	Deformable image registration between pathological images and MR image via an optical macro image. Pathology Research and Practice, 2016, 212, 927-936.	2.3	18
93	Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1â€“mutated Human Gliomas. Radiology, 2020, 294, 589-597.	7.3	18
94	Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).. Journal of Clinical Oncology, 2021, 39, 7506-7506.	1.6	18
95	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal of Neuro-Oncology, 2017, 132, 181-188.	2.9	16
96	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. Npj Precision Oncology, 2017, 1, .	5.4	16
97	Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers. Neuro-Oncology Practice, 2020, 7, 490-497.	1.6	16
98	Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2013-2013.	1.6	16
99	Genomic profiling of brain metastases: current knowledge and new frontiers. Chinese Clinical Oncology, 2015, 4, 22.	1.2	16
100	Cytotoxic chemotherapy: Advances in delivery, pharmacology, and testing. Current Oncology Reports, 2000, 2, 445-453.	4.0	14
101	High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 884-888.	0.4	14
102	Effects of cediranib (VEGF signaling inhibitor) on edema in newly diagnosed glioblastoma patients during initial chemoradiation.. Journal of Clinical Oncology, 2012, 30, 2012-2012.	1.6	14
103	Primary Central Nervous System Lymphoma. Neurologic Clinics, 2018, 36, 517-532.	1.8	13
104	Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. Radiology, 2022, 302, 410-418.	7.3	13
105	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro-Oncology, 2022, 24, 1140-1149.	1.2	13
106	Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss. Neuro-Oncology, 2018, 20, 289-291.	1.2	12
107	An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7ÂT. Scientific Reports, 2020, 10, 15029.	3.3	12
108	Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Scientific Reports, 2018, 8, 17062.	3.3	11

#	Article	IF	Citations
109	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neuro-Oncology Practice, 2018, 5, 64-68.	1.6	10
110	Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Scientific Reports, 2019, 9, 139.	3.3	9
111	Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. Oncologist, 2020, 25, 747-e1273.	3.7	9
112	Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2019-2019.	1.6	9
113	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. Journal of Clinical Neuroscience, 2016, 31, 99-105.	1.5	8
114	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neuro-Oncology Advances, 2020, 2, vdaa157.	0.7	8
115	Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.. Journal of Clinical Oncology, 2020, 38, 3615-3615.	1.6	8
116	Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2009-2009.	1.6	7
117	Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2029-2029.	1.6	7
118	International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) Study on Low-Grade Primary Central Nervous System Lymphoma in Immunocompetent Patients.. Blood, 2005, 106, 3343-3343.	1.4	7
119	Intra-axial brain tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 253-274.	1.8	6
120	MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab060.	0.7	5
121	Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity. Current Oncology Reports, 2021, 23, 132.	4.0	5
122	Antiangiogenic Therapy for Glioblastoma: The Challenge of Translating Response Rate into Efficacy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e71-e78.	3.8	5
123	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. Neuro-Oncology, 2020, 22, ii44-ii44.	1.2	5
124	ACTR-61. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi27-vi27.	1.2	4
125	Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.. Journal of Clinical Oncology, 2020, 38, 8042-8042.	1.6	4
126	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. Neuro-Oncology, 2021, 23, vi59-vi59.	1.2	4

#	Article	IF	Citations
127	Neuro-oncology update: 2005. Current Opinion in Neurology, 2005, 18, 631.	3.6	3
128	Case 17-2012. New England Journal of Medicine, 2012, 366, 2112-2120.	27.0	3
129	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. Neuro-Oncology, 2018, 20, vi19-vi19.	1.2	3
130	Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. Oncologist, 2019, 24, 402-413.	3.7	3
131	Intracranial Foreign Body Granuloma Mimicking Brain Tumor Recurrence: A Case Series. Oncologist, 2021, 26, e893-e897.	3.7	3
132	Integrating Advanced Practice Providers in an Academic Department of Neurology. Neurology: Clinical Practice, 2021, 11, 10.1212/CPJ.0000000000001077.	1.6	3
133	Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphoma. Neuro-Oncology, 2022, 24, 482-491.	1.2	3
134	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. Neuro-Oncology, 2020, 22, ii43-ii44.	1.2	3
135	High-Dose Methotrexate, Rituximab, and Temozolomide (MRT) for Patients with Primary CNS Lymphoma (PCNSL).. Blood, 2009, 114, 1672-1672.	1.4	3
136	Impact of adjuvant anti-VEGF therapy on treatment-related pseudoprogression in patients with newly diagnosed glioblastoma receiving chemoradiation with or without anti-VEGF therapy.. Journal of Clinical Oncology, 2012, 30, 2025-2025.	1.6	3
137	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2054-2054.	1.6	3
138	Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.. Journal of Clinical Oncology, 2019, 37, 3005-3005.	1.6	3
139	Factors associated with psychological distress in caregivers of patients with malignant gliomas. Supportive Care in Cancer, 2022, 30, 5811-5820.	2.2	3
140	Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2030-2030.	1.6	3
141	ATPS-852-HYDROXYGLUTARATE DEPLETION IS NOT SUFFICIENT TO INHIBIT GROWTH OF SEVERAL PROGRESSIVE IDH1 MUTANT SOLID CANCER TYPES. Neuro-Oncology, 2015, 17, v37.2-v37.	1.2	2
142	PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi186-vi186.	1.2	2
143	Is it time to revisit R-CHOP for primary CNS lymphoma?. Blood, 2019, 134, 221-222.	1.4	2
144	Isolated Brain Parenchyma Relapse of Non-Hodgkinâ€™s Lymphoma (NHL): A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).. Blood, 2006, 108, 2026-2026.	1.4	2

#	Article	IF	Citations
145	ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples. Blood, 2014, 124, 5219-5219.	1.4	2
146	Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 2015-2015.	1.6	2
147	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2014, 32, 2031-2031.	1.6	2
148	Intratumoral activity of ONC201 in adult recurrent glioblastoma patients.. Journal of Clinical Oncology, 2018, 36, e14034-e14034.	1.6	2
149	Improving Dâ€2â€hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RFâ€receive/B₀â€shim array coils at 3â€‰T. NMR in Biomedicine, 2022, 35, e4621.	2.8	2
150	Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.. Journal of Clinical Oncology, 2020, 38, 3617-3617.	1.6	2
151	HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2020, 22, iii347-iii347.	1.2	2
152	In Vivo Absolute Metabolite Quantification Using a Multiplexed <scp>ERETICâ€RX</scp> Array Coil for Wholeâ€Brain <scp>MR</scp> Spectroscopic Imaging. Journal of Magnetic Resonance Imaging, 2022, 56, 121-133.	3.4	2
153	Deep Learning Super-resolution MR Spectroscopic Imaging of Brain Metabolism and Mutant IDH Glioma. Neuro-Oncology Advances, 0, , .	0.7	2
154	Principles of pharmacotherapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 149-162.	1.8	1
155	ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi20-vi21.	1.2	1
156	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. Neuro-Oncology, 2019, 21, vi111-vi111.	1.2	1
157	Innovative Therapeutic Strategies for Primary CNS Lymphoma. Current Treatment Options in Neurology, 2021, 23, 1.	1.8	1
158	Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2010-2010.	1.6	1
159	Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.. Journal of Clinical Oncology, 2014, 32, 2020-2020.	1.6	1
160	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2025-2025.	1.6	1
161	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2015, 33, TPS2080-TPS2080.	1.6	1
162	Integrated clinical experience with ONC201 in H3 K27M glioma.. Journal of Clinical Oncology, 2018, 36, 2059-2059.	1.6	1

#	Article	IF	Citations
163	Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2005-2005.	1.6	1
164	MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.. Journal of Clinical Oncology, 2018, 36, e14041-e14041.	1.6	1
165	CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2020, 22, ii50-ii51.	1.2	1
166	Response to C. Massard et al. Journal of Clinical Oncology, 2012, 30, 563-564.	1.6	0
167	AT-37PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA. Neuro-Oncology, 2014, 16, v16-v17.	1.2	0
168	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. Neuro-Oncology, 2014, 16, v16-v16.	1.2	0
169	Computationally simple analysis of matched, outcomeâ€based studies of ordinal disease states. Statistics in Medicine, 2015, 34, 2514-2527.	1.6	0
170	HCP-03NEWLY DIAGNOSED SINGLE BRAIN MASS â€“ IMPLEMENTATION AND PERFORMANCE OF A HOSPITAL-WIDE MANAGEMENT PATHWAY. Neuro-Oncology, 2015, 17, v101.3-v101.	1.2	0
171	ANGI-04Olig2 REGULATES Wnt7b EXPRESSION AND VASCULATURE CHARACTERISTICS IN GLIOMA. Neuro-Oncology, 2015, 17, v41.4-v41.	1.2	0
172	NIMG-29RADIOLABELED TEMOZOLOMIDE CAN MEASURE BEVACIZUMAB INDUCED VASCULAR MODULATION IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2015, 17, v160.1-v160.	1.2	0
173	HCP-12IMPROVING THE EFFICIENCY OF MOLECULAR TESTING FOR EXPEDITED BRAIN TUMOR PATIENT MANAGEMENT AND CLINICAL TRIAL ENROLLMENT. Neuro-Oncology, 2015, 17, v103.4-v104.	1.2	0
174	NIMG-22. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA DURING CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE. Neuro-Oncology, 2016, 18, vi128-vi129.	1.2	0
175	NIMG-42. PENETRATION OF RADIOLABELED TEMOZOLOMIDE CORRELATES WITH CONTRAST ENHANCEMENT IN PATIENTS WITH RECURRENT GBM TREATED WITH BEVACIZUMAB. Neuro-Oncology, 2016, 18, vi133-vi133.	1.2	0
176	EXTH-14. THE ALKYLATING CHEMOTHERAPEUTIC TEMOZOLOMIDE INDUCES METABOLIC STRESS AND POTENTIATES NAD+ DEPLETION-MEDIATED CELL DEATH IN IDH1 MUTANT CANCERS. Neuro-Oncology, 2017, 19, vi75-vi75.	1.2	0
177	NIMG-01. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM ANTI-VEGF MONOTHERAPY IN GLIOBLASTOMA AT FIRST OR SECOND RELAPSE. Neuro-Oncology, 2017, 19, vi142-vi143.	1.2	0
178	Neuro-Oncology. Seminars in Neurology, 2018, 38, 003-004.	1.4	0
179	QOLP-23. PALLIATIVE CARE AND END OF LIFE HEALTHCARE UTILIZATION IN PATIENTS WITH INCURABLE PRIMARY MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2018, 20, vi219-vi219.	1.2	0
180	EPID-11. PROGRESSION OF IDH MUTANT GLIOMA AFTER FIRST RECURRENCE: DEVELOPMENT OF A FEASIBLE CLINICAL TRIAL ENDPOINT IN THE RECURRENT SETTING. Neuro-Oncology, 2018, 20, vi82-vi82.	1.2	0

#	Article	IF	Citations
181	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. Neuro-Oncology, 2018, 20, vi56-vi57.	1.2	0
182	CSIG-34. PI3 KINASE PATHWAY ACTIVATION PROMOTES MALIGNANT PROGRESSION IN OLIGODENDROGLIAL TUMORS. Neuro-Oncology, 2018, 20, vi50-vi50.	1.2	0
183	QOLP-21. THE RELATIONSHIP BETWEEN CAREGIVING BURDEN AND ANXIETY SYMPTOMS IN CAREGIVERS OF PATIENTS WITH MALIGNANT GLIOMAS. Neuro-Oncology, 2018, 20, vi219-vi219.	1.2	0
184	NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE. Neuro-Oncology, 2018, 20, vi191-vi191.	1.2	0
185	ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2018, 20, vi18-vi19.	1.2	0
186	BSCI-10. NEUROLOGICAL DYSFUNCTION CAUSED BY BRAIN TUMOR-GENERATED SOLID STRESS IS REVERSED BY LITHIUM. Neuro-Oncology Advances, 2019, 1, i2-i3.	0.7	0
187	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. Neuro-Oncology, 2019, 21, vi58-vi59.	1.2	0
188	The 1994 National Cancer Instituteâ€™s strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas.. Journal of Clinical Oncology, 2021, 39, 2003-2003.	1.6	0
189	Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group.. Blood, 2004, 104, 1372-1372.	1.4	0
190	Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. Blood, 2011, 118, 959-959.	1.4	0
191	Response of nonenhancing regions in glioblastoma to VEGF-signaling inhibitor cediranib correlates with tumor infiltration.. Journal of Clinical Oncology, 2012, 30, 3036-3036.	1.6	0
192	Update on Glioma Treatments in the United States. Japanese Journal of Neurosurgery, 2013, 22, 590-596.	0.0	0
193	Longitudinal diffusion MRI in PCNSL treated with methotrexate, rituximab, and temozolomide (MRT).. Journal of Clinical Oncology, 2014, 32, 8579-8579.	1.6	0
194	Targetable signaling pathway mutations and progression of IDH-mutant glioma.. Journal of Clinical Oncology, 2014, 32, 2061-2061.	1.6	0
195	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results.. Journal of Clinical Oncology, 2014, 32, 2027-2027.	1.6	0
196	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.. Journal of Clinical Oncology, 2014, 32, e13022-e13022.	1.6	0
197	Characterizing glioma microenvironment with ultra-high gradient diffusion MRI.. Journal of Clinical Oncology, 2017, 35, 2050-2050.	1.6	0
198	Health care utilization and end of life care in patients with primary malignant brain tumors.. Journal of Clinical Oncology, 2018, 36, e14072-e14072.	1.6	0

#	Article	IF	Citations
199	MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with bavituximab, radiation, and temozolomide.. Journal of Clinical Oncology, 2020, 38, 2546-2546.	1.6	0
200	CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGhT) EXPERIENCE. Neuro-Oncology, 2021, 23, vi68-vi69.	1.2	0
201	BIOM-09. MYO-INOSITOL LEVELS ON MR SPECTROSCOPY CAN PREDICT FAILURE OF ANTI-ANGIOGENIC TREATMENT IN RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi11-vi12.	1.2	0
202	TAMI-29. MR SPECTROSCOPY MEASURES OF LAC/NAA AND NAA/CHO DIFFERENTIATE SURVIVORSHIP IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH ANTI-ANGIOGENIC THERAPY. Neuro-Oncology, 2021, 23, vi204-vi204.	1.2	0
203	PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE. Neuro-Oncology, 2020, 22, ii164-ii164.	1.2	0
204	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2020, 22, ii45-ii46.	1.2	0
205	INNV-40. REAL WORLD INTEGRATION OF THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN CLINICAL PRACTICE IN PATIENTS WITH IDH-WT GBM. Neuro-Oncology, 2021, 23, vi114-vi114.	1.2	0
206	Central nervous system lymphoma. , 0, , 449-461.		0